Tophaceous gout associated with bempedoic acid Authors: Parag N Patel, Didar Singh Published: 2026 An 87-year-old woman presented to the emergency department with progressive painful nodular swelling and erythema over the first and second distal interphalangeal joints of the right hand that had evolved over the past 2 to 3 weeks (Figure 1A). Her medical history included rheumatoid arthritis, coronary artery disease, and stage 4 chronic kidney disease. She was not taking diuretics or other urateraising medications. Four months earlier, she had started bempedoic acid 180 mg by mouth daily for hyperlipidemia in the setting of statin intolerance. (A) Photograph of the right hand of an 87-year-old woman with tophaceous gout, showing firm, chalky white nodular deposits involving the distal phalanges of the first and second digits; this was associated with her use of bempedoic acid. (B) Aspirate of distal digital nodule, yielding chalky, paste-like material consistent with monosodium urate crystal deposition. The patient was referred to our internal medicine service. We aspirated a digital nodule that yielded chalky material containing numerous monosodium urate crystals (Figure 1B). Cultures were sterile. Her serum uric acid level was elevated (11.7 [reference 3.4 to 7.0] mg/dL), with no previous baseline available. Radiographs showed soft tissue swelling and degenerative joint disease without erosions. We diagnosed tophaceous gout. The patient’s only other identified risk factors for gout were her age and kidney disease. We calculated her Naranjo Causality Assessment Scale score of 5, indicating a probable association with her taking bempedoic acid. It was discontinued, and we prescribed oral prednisolone 40 mg once daily for 10 days, avoiding colchicine and urate-lowering therapy owing to her advanced chronic kidney disease. Within 2 weeks the nodules regressed, and uric acid levels fell within the reference range. At follow-up visits 1 month and 2 months after treatment, she had no recurrence. Bempedoic acid is indicated to decrease levels of low-density lipoprotein cholesterol in adults with cardiovascular disease or statin intolerance, approved by Health Canda in 2025.1 It inhibits renal tubular organic anion transporter 2, reducing uric acid excretion and increasing the risk of hyperuricemia and gout. Clinical trials have reported gout in about 3% of treated patients,2 although adverse event rates may be underestimated and not fully reflect risk in older patients with advanced chronic kidney disease. Chronic kidney disease independently reduces urate clearance, and even modest drug-related increases may be clinically significant in patients with limited renal reserve. This case highlights the need for individualized risk assessment when prescribing bempedoic acid.3 Footnotes Competing interests: None declared. This article has been peer reviewed. The authors have obtained patient consent. References